Meet Cogstate experts at these upcoming industry events around the globe.
During the 2018 NORD Rare Summit, over 700 leaders from FDA, NIH, industry, patient groups, payers and research institutions will address the New Era of Patient-Focused Innovation. Together, NORD Rare Summit attendees will explore the new and innovative ways in which patients and caregivers are helping drive progress for the rare disease community.
Want to receive the latest Cogstate news? Sign up for our newsletter:
Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company’s clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For nearly 20 years, Cogstate has proudly supporting the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world.